Market Place
Sourcing Support
Celltrion Presents Phase III Data for CT-41 & CT-P47 Biosimilars
18 Nov 2024 //
PR NEWSWIRE
Samsung Gets Positive CHMP Opinion for Denosumab Biosimilars
15 Nov 2024 //
GLOBENEWSWIRE
Sandoz`s Biologic Jubbonti (Denosumab-bbdz) Receives Suppl Approval in US
24 Oct 2024 //
FDA
Sandoz`s Biologic Wyost (Denosumab-bbdz) Receives Suppl Approval in US
24 Oct 2024 //
FDA
EMA Accepts AVT03 Marketing Application For Prolia Biosimilar
10 Oct 2024 //
GLOBENEWSWIRE
Teva Prolia Biosimilar Accepted For Review By FDA And EMA
08 Oct 2024 //
GLOBENEWSWIRE
STADA And Alvotech Launch Uzpruvo, First Ustekinumab Biosimilar In EU
22 Jul 2024 //
GLOBENEWSWIRE
Alvotech Reports Positive Results For AVT03, Biosimilar To Prolia And Xgeva
02 Jul 2024 //
GLOBENEWSWIRE
Alvotech and STADA add to strategic alliance through denosumab partnership
12 Jun 2024 //
PRESS RELEASE
Samsung Biosimilar Sb16 Prolia: Switching Period Results At Ects 2024
27 May 2024 //
GLOBENEWSWIRE
Dr. Reddy’s and Novartis sign distribution agreement for anti-diabetes products
27 May 2024 //
PHARMACEUTICAL TECHNOLOGY
Henlius Xgeva® Prolia® Biosimilar: Ema Filings With Organon Validated
24 May 2024 //
BUSINESSWIRE
EC approves Sandoz’s biosimilars for bone-related ailments
23 May 2024 //
PHARMACEUTICAL TECHNOLOGY
Sandoz’s Wyost and Jubbonti Granted EC Marketing Authorization
22 May 2024 //
GLOBENEWSWIRE
Alvotech, Dr. Reddy`s ink pact for commercialisation of denosumab
21 May 2024 //
PRESS RELEASE
MAIWEIJIAN becomes first approved biosimilar of Denosumab (120mg) in China
09 Apr 2024 //
BIOSPECTRUMASIA
MAIWEIJIAN, First Approved Biosimilar of Denosumab (120mg) in China
08 Apr 2024 //
PR NEWSWIRE
Phase 3 Comparative Clinical Study of Prolia® and Xgeva Met Primary Endpoints
08 Apr 2024 //
BUSINESSWIRE
Sandoz wins FDA approval for first two biosimilars for Amgen`s bone drug
06 Mar 2024 //
ENDPTS
Sandoz`s Biologic Jubbonti (denosumab-bbdz) Receives Approval in the U.S.
05 Mar 2024 //
FDA
Mabwell Publishes the Phase III Study Results on Its Denosumab Biosimilar
21 Feb 2024 //
PR NEWSWIRE
FDA slaps boxed warning on Amgen`s osteoporosis drug Prolia
20 Jan 2024 //
FIERCE PHARMA
Amneal Adds Two Denosumab Biosimilars to U.S. Pipeline
12 Oct 2023 //
BUSINESSWIRE
Sandoz Marketing Authorization Applications for denosumab accepted by EMA
25 May 2023 //
GLOBENEWSWIRE
New Data From Amgen`S Prolia® (Denosumab) Demonstrates Significant Reduction
08 May 2023 //
PR NEWSWIRE
Amgen takes Novartis` Sandoz to court over bone med biosimilar
06 May 2023 //
FIERCE PHARMA
Amgen`s denosumab shows promise in small, NIH-funded rare bone disease study
06 Apr 2023 //
ENDPTS
The World`s Second Approved Biosimilars of Denosumab (MAILISHU)
03 Apr 2023 //
PR NEWSWIRE
Sandoz License Application for proposed biosimilar denosumab accepted by US FDA
06 Feb 2023 //
GLOBENEWSWIRE
BeiGene Announces Expansion of Coverage on China’s Reimbursement Drug List
18 Jan 2023 //
PRESS RELEASE
Amgen`s Biologic Prolia (Denosumab) Receives Approval in U.S.
03 Jan 2023 //
FDA
Mabwell Partners with Binnopharm to Market 9MW0113, 9MW0321 and 9MW0311
20 Dec 2022 //
PR NEWSWIRE
Sandoz announces further progress on its biosimilar pipeline,release +ve results
19 Sep 2022 //
GLOBENEWSWIRE
Lupin, DKSH enter pact to commercials Alvotech biosimilars in Philippines
07 Sep 2022 //
ECONOMIC TIMES
Lupin and DKSH sign exclusive licensing and supply agreement to market five
06 Sep 2022 //
EXPRESS PHARMA
Lupin Liquidating Japan JV With Yoshindo, Partners I’Rom For Denosumab
29 Aug 2022 //
RAPS
Lupin, I’rom pharma enter into licensing agreement for Denosumab biosimilar
25 Aug 2022 //
HEALTH ET
Amgen’s marketing for cancer bone med Xgeva shifts to patients’ stories
15 Feb 2022 //
ENDPTS
Richter, Hikma sign excl. commercialisation & license agreement for denosumab
09 Dec 2021 //
PRNEWSWIRE
Theramex announces license agreement for Prolia biosimilar in EU and Australia
14 Jun 2021 //
GOODWIN
Theramex UK announces a license and supply agreement with Enzene Biosciences
10 Jun 2021 //
PHARMIWEB
China makes new inclusions in national reimbursement drug list
28 Dec 2020 //
BIOSPECTRUMASIA
China makes new inclusions in national reimbursement drug list
28 Dec 2020 //
BIOSPECTRUMASIA
Luye Pharma Starts a Phase III Clinical Study for Denosumab Injection (LY01011)
15 Dec 2020 //
LUYE
Could Amgen`s Xgeva boost immunotherapy in breast cancer?
14 Dec 2020 //
FIERCEBIOTECH
BeiGene Announces the Approval of XGEVA® (Denosumab) in China
20 Nov 2020 //
BIOSPACE
Samsung Bioepis Initiates Ph 1 Trial for SB16, Proposed Biosimilar to Prolia
10 Nov 2020 //
PRESS RELEASE
First Patient Dosed in Ph 1 Clinical Trial of Henlius Denosumab Biosimilar HLX14
10 Nov 2020 //
PIPELINEREVIEW
Common osteoporosis treatments could reduce incidence of COVID-19
04 Nov 2020 //
EUROPEANPHARMACEUTICALREVIEW
Henlius Biotech Gets NMPA Nod for Denosumab Biosimilar
25 Jun 2020 //
CENTERFORBIOSIMILARS
Amgen`s Xgeva (Denosumab) Receives Supplemental Approval In US
16 Jun 2020 //
FDA
Amgen`s Prolia (Denosumab) Receives Supplemental Approval In US
16 Jun 2020 //
FDA
JHL Biotech begins Australian phase I trial of denosumab biosimilar JHL1266
20 May 2020 //
PHARMABIZ
Amgen`s Xgeva (Denosumab ) Receives Supplemental Approval In US
13 Feb 2020 //
FDA
Amgen`s Prolia (Denosumab ) Receives Supplemental Approval In US
13 Feb 2020 //
FDA
Amgen Commences Strategic Collaboration With BeiGene to Expand Oncology in China
03 Jan 2020 //
PRESS RELEASE
Denosumab Use in Myeloma Soars for No Obvious Reason
16 Dec 2019 //
MEDPAGETODAY
Amgen teams up with BeiGene in cancer a $2.7B stake
01 Nov 2019 //
ENDPTS
Amgen Inc.`s Xgeva (Denosumab) Receives Supplemental Approval in US
03 Oct 2019 //
FDA
